SHANGHAI, Aug. 7, 2025 /PRNewswire/ — Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from…
